Wealthy Norwegians flee to Switzerland to evade high wealth taxes, with their bankers following
Steep increases in wealth and dividend taxes by Norway’s left-leaning government have prompted dozens of the Nordic nation’s rich to move to another prosperous, mountainous country to the south. Their bankers now have Switzerland in their sights too. DNB Bank ASA, the country’s largest lender,…#norway #nordic #switzerland #dnbbankasa #norwegian #zurich #abgsundalcollier #lucerne #hallgeirhollup #dnb (Source: Reuters: Health)
Source: Reuters: Health - April 19, 2024 Category: Consumer Health News Source Type: news
From killer cantaloupe to bacteria-infested beef: Watchdog names the 10 most dangerous food recalls and poisoning outbreaks of 2023
Food-borned illnesses sickened thousands of people in the US last year, with pathogens including salmonella and E. coli lurking in cantaloupe, alfalfa sprouts, ground beef, and more. (Source: the Mail online | Health)
Source: the Mail online | Health - March 2, 2024 Category: Consumer Health News Source Type: news
New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news
Tensions are bubbling up at thirsty Arizona alfalfa farms as foreign firms exploit unregulated water
A blanket of bright green alfalfa spreads across western Arizona's McMullen Valley, ringed by rolling mountains and warmed by the hot desert sun. Matthew Hancock's family has used groundwater to grow forage crops here for more than six decades. They're long accustomed to caprices of Mother Nature…#arizona #mcmullenvalley #matthewhancock #wenden #emirati #aldahra #hancock #phoenix #western #unitednations (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2023 Category: Consumer Health News Source Type: news
Do women prefer having female radiologists perform breast ultrasound?
Most women undergoing breast ultrasound are unconcerned about whether a radiologist is male or female, according to research published November 8 in PLOS One. A team led by Elisabeth Sartoretti, MD, from the University of Lucerne in Switzerland found that nearly three out of four women reported that it made no difference whether a female or male radiologist performed a breast ultrasound exam. “It would appear that women examined by male radiologists are less selective about the sex of the examining radiologist,” Sartoretti and colleagues wrote. The researchers noted that there is a trend toward fewer male radiolo...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Imaging Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to afliberceptVabysmo also demonstrated rapid and robust drying of retinal fluidAdditional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate isin line withother broadly used intravitreal treatmentsBasel, 27 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) an...
Source: Roche Investor Update - October 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to afliberceptVabysmo also demonstrated rapid and robust drying of retinal fluidAdditional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate isin line withother broadly used intravitreal treatmentsBasel, 27 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) an...
Source: Roche Media News - October 27, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Media News - October 10, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Investor Update - October 10, 2023 Category: Pharmaceuticals Source Type: news
The Man Who Thinks He Can Live Forever
In a neat little neighborhood in Venice, Calif., there’s a block of squat, similar homes, filled with mortals spending their finite days on the planet eating pizza with friends, blowing out candles on birthday cakes, and binging late-night television. Halfway down the street, there’s a cavernous black modern box. This is where Bryan Johnson is working on what he calls “the most significant revolution in the history of Homo sapiens.”
[time-brightcove not-tgx=”true”]
Johnson, 46, is a centimillionaire tech entrepreneur who has spent most of the last three years in pursuit of a si...
Source: TIME: Health - September 20, 2023 Category: Consumer Health News Authors: Charlotte Alter Tags: Uncategorized feature Source Type: news
The Great Salt Lake is shrinking rapidly, and Utah has failed to stop it, a lawsuit contends
Utah officials have pushed the Great Salt Lake to the brink of an ecological collapse because they allowed upstream water to be diverted for decades to farmers growing alfalfa, hay and other crops, according to a lawsuit filed Wednesday by a coalition of environmental groups. The conservationists…#utah #greatsaltlake #mississippiriver #nt #legislature #earthjustice #utahriverscouncil #utahphysicians #brianmoench #emmawilliams (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2023 Category: Consumer Health News Source Type: news
Amid record heat, solar farms help ease the strain on U.S. power grids
Rosamond, California — Next to the rows of alfalfa, another type of farm is taking root in Southern California's Kern County, one that's harvesting clean, renewable energy. Solar Star, one of the largest solar farms in the U.S., has a peak output of 586 megawatts. "These panels track the sun all…#rosamond #southerncalifornia #kerncounty #solarstar #aliciaknapp #bherenewables #knapp #pjminterconnection #loreleioviatt #cbsnews (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Media News - July 20, 2023 Category: Pharmaceuticals Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Investor Update - July 20, 2023 Category: Pharmaceuticals Source Type: news
